{"id":"mri-contrast-enhancing-agents","safety":{"commonSideEffects":[{"rate":null,"effect":"Gadolinium retention in tissues"},{"rate":"rare","effect":"Nephrogenic systemic fibrosis (in patients with severe renal impairment)"},{"rate":"<1","effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These agents work by shortening the relaxation times (T1 or T2) of hydrogen nuclei in tissue, thereby increasing signal intensity in MRI scans. Gadolinium-based agents are most common, accumulating in areas of interest and enhancing image contrast to reveal lesions, tumors, or vascular abnormalities that would otherwise be difficult to visualize.","oneSentence":"MRI contrast-enhancing agents improve visualization of anatomical structures and pathology by altering the magnetic properties of nearby water molecules during magnetic resonance imaging.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:14.170Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Enhancement of MRI imaging in central nervous system lesions"},{"name":"Enhancement of MRI imaging in cardiovascular and musculoskeletal pathology"},{"name":"General diagnostic imaging enhancement across multiple organ systems"}]},"trialDetails":[{"nctId":"NCT06141473","phase":"PHASE3","title":"Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis","status":"RECRUITING","sponsor":"Sanofi","startDate":"2023-12-13","conditions":"Multiple Sclerosis","enrollment":1600},{"nctId":"NCT06141486","phase":"PHASE3","title":"Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis","status":"RECRUITING","sponsor":"Sanofi","startDate":"2023-12-27","conditions":"Multiple Sclerosis","enrollment":900},{"nctId":"NCT07066436","phase":"EARLY_PHASE1","title":"ImmunoMRI for Assessment of Tumor-associated Macrophages","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Vienna","startDate":"2025-10","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":60},{"nctId":"NCT07009743","phase":"","title":"O-RADS MRI System on Early Detection of Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Gynecologic Oncology Group","startDate":"2025-01-01","conditions":"Ovarian Cancer (OvCa), Ovarian Cancer Metastatic","enrollment":2549},{"nctId":"NCT00777686","phase":"","title":"Measuring Non-Enhancing Glioblastoma Progression","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-08","conditions":"Brain Tumor, Glioblastoma","enrollment":7}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MRI contrast-enhancing agents","genericName":"MRI contrast-enhancing agents","companyName":"Medical University of Vienna","companyId":"medical-university-of-vienna","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MRI contrast-enhancing agents are used in clinical trials to study various conditions, including Ovarian Cancer, Brain Tumor, and DLBCL - Diffuse Large B Cell Lymphoma. These agents are part of the O-RADS MRI system, which is being studied for its potential in early detection of Ovarian Cancer in a prospective, multicenter study.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}